Last update 21 Jun 2024
Luliconazole
Last update 21 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Luconac Solution, Luliconazole (JAN/USAN/INN), Lulifin + [12] |
Target |
Mechanism fungal CYP51A1 inhibitors(Fungal CYP51A1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (11 Apr 2005), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC14H9Cl2N3S2 |
InChIKeyYTAOBBFIOAEMLL-REQDGWNSSA-N |
CAS Registry187164-19-8 |
Related
15
Clinical Trials associated with LuliconazoleA Comparative study to evaluate the efficacy and safety of topical Luliconazole versus topical Ciclopirox olamine among patients with Tinea corporis/cruris - NIL
A randomized study to evaluate and compare the efficacy of emollient versus topical luliconazole in the maintenance of remission of recurrent dermatophytosis after adequate systemic treatment.
COMPARISION OF EFFICACY OF LULICONAZOLE 1% W/W Vs AMOROLFINE 0.25% W/W IN THE TREATMENT OF TINEA CRURIS.A SINGLE CENTRE , RANDOMISED , DOUBLE BLIND , NON INFERIORITY STUDY.
100 Clinical Results associated with Luliconazole
Login to view more data
100 Translational Medicine associated with Luliconazole
Login to view more data
100 Patents (Medical) associated with Luliconazole
Login to view more data
185
Literatures (Medical) associated with Luliconazole01 Mar 2024International journal of biological macromolecules
Fabrication of gelatin coated polycaprolactone nanofiber scaffolds co-loaded with luliconazole and naringenin for treatment of Candida infected diabetic wounds
Article
Author: Manjit, Manjit ; Jha, Abhishek ; Kumar, Krishan ; Tiwari, Punit ; Koch, Biplob ; Singh, Virendra ; Mishra, Brahmeshwar ; Bharti, Kanchan ; Tilak, Ragini ; Kumar, Manish
The current study focuses on the development of gelatin-coated polycaprolactone (PCL) nanofibers co-loaded with luliconazole and naringenin for accelerated healing of infected diabetic wounds. Inherently, PCL nanofibers have excellent biocompatibility and biodegradation profiles but lack bioadhesion characteristics, which limits their use as dressing materials. So, coating them with a biocompatible and hydrophilic material like gelatin can improve bioadhesion. The preparation of nanofibers was done with the electrospinning technique. The solid state characterization and in-vitro performance assessment of nanofibers indicate the formation of uniformly interconnected nanofibers of 200-400 nm in diameter with smooth surface topography, excellent drug entrapment, and a surface pH of 5.6-6.8. The antifungal study showed that the nanofiber matrix exhibits excellent biofilm inhibition activity against several strains of Candida. Further, in-vivo assessment of nanofiber performance on C. albicans infected wounds in diabetic rats indicated accelerated wound healing efficacy in comparison to gauge-treated groups. Additionally, a higher blood flow and rapid re-epithelialization of wound tissue in the treatment group corroborated with the results obtained in the wound closure study. Overall, the developed dual-drug-loaded electrospun nanofiber mats have good compatibility, surface properties, and excellent wound healing potential, which can provide an extra edge in the management of complex diabetic wounds.
01 Feb 2024Colloids and surfaces. B, Biointerfaces
Development of microemulgel formulations with varied permeation enhancers for transungual delivery of luliconazole in onychomycosis management
Article
Author: Behera, Amulyaratna ; Dixit, Pradyumna Kumar ; Habibullah, Sk ; Giri, Yashwant ; Mahalik, Gyanranjan ; Mohanty, Biswaranjan
Luliconazole-loaded microemulgels containing different permeation enhancers were formulated for transungual drug delivery for the management of onychomycosis, onychomycosis, which affects nails. The physicochemical properties like droplet size, zeta potential, pH, viscosity, spreadability, extrudability, oil binding capacity, drug content, and microscopic study were evaluated. The Pseudo-ternary phase diagram was constructed for the formulation of microemulsions (MEs) by keeping the Km ratio constant at 3:1 and characterized for clarity, mean droplet size, zeta potential, viscosity, pH, transmittance, refractive index, and stability. The ME mean droplet size and zeta potential were found in the range of 38.78 to 171.4 nm, and 0.00 to - 6.6 mV, respectively. Prepared MEs were converted into microemulgel by adding a 2.5% gelling agent (Carbapol 934) in the external phase, and a drug release study was conducted. Formulation E3 showed better drug release and was chosen as the control. Four different penetration enhancers were added separately within E3 and further evaluated for pH, viscosity, spreadability, extrudability, oil binding capacity, drug content, microscopic study, Compatibility study, XRD, and DSC. A favorable docking score was observed between luliconazole and Lanosterol 14-alpha-demethylase. In-vitro cumulative drug release at the end of 24 h from E3-SS, containing sodium sulfide as a penetration enhancer, was found to be 94.70% and was 2 times more than the control formulation. Ex-vivo transungual permeation studies through cutting nail clippings were found to be in the range of 28.18 - 36.52 µg/mm2. The microemulgels tagged as E3, E3-SS, and E3-SL showed a significant zone of inhibition against Candida albicans and Aspergillus fumigatus as compared to the marketed formulation.
01 Feb 2024International journal of biological macromolecules
Formulation and characterization of polyvinyl alcohol/chitosan composite nanofiber co-loaded with silver nanoparticle & luliconazole encapsulated poly lactic-co-glycolic acid nanoparticle for treatment of diabetic foot ulcer
Article
Author: Manjit, Manjit ; Tiwari, Punit ; Koch, Biplob ; Singh, Virendra ; Mishra, Brahmeshwar ; Tilak, Ragini ; Kumar, Krishan ; Bharti, Kanchan ; Jha, Abhishek ; Kumar, Manish
Chronic wounds are prone to fungal infections, possess a significant challenge, and result in substantial mortality. Diabetic wounds infected with Candida strains are extremely common. It can create biofilm at the wound site, which can lead to antibiotic resistance. As a result, developing innovative dressing materials that combat fungal infections while also providing wound healing is a viable strategy to treat infected wounds and address the issue of antibiotic resistance. Present work proposed anti-infective dressing material for the treatment of fungal strains Candida-infected diabetic foot ulcer (DFU). The nanofiber was fabricated using polyvinyl Alcohol/chitosan as hydrogel base and co-loaded with silver nanoparticles (AgNP) and luliconazole-nanoparticles (LZNP) nanoparticles, prepared using PLGA. Fabricated nanofibers had pH close to target area and exhibited hydrophilic surface suitable for adhesion to wound area. The nanofibers showed strong antifungal and antibiofilm properties against different strains of Candida; mainly C. albicans, C. auris, C. krusei, C. parapsilosis and C. tropicalis. Nanofibers exhibited excellent water retention potential and water vapour transmission rate. The nanofibers had sufficient payload capacity towards AgNP and LZNP, and provided controlled release of payload, which was also confirmed by in-vivo imaging. In-vitro studies confirmed the biocompatibility and enhanced proliferation of Human keratinocytes cells (HaCaT). In-vivo studies showed accelerated wound closure by providing ant-infective action, supporting cellular proliferation and improving blood flow, all collectively contributing in expedited wound healing.
1
News (Medical) associated with Luliconazole10 Sep 2015
First in Class
100 Deals associated with Luliconazole
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01980 | Luliconazole |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Tinea Manus | US | 20 Feb 2018 | |
| Onychomycosis | JP | 22 Jan 2016 | |
| Candidiasis, Cutaneous | CN | 27 Jun 2012 | |
| Mycoses | KR | 01 Feb 2010 | |
| Tinea corporis | JP | 31 Jul 2005 | |
| tinea cruris | JP | 31 Jul 2005 | |
| Tinea Pedis | JP | 31 Jul 2005 | |
| Candidiasis | JP | 11 Apr 2005 | |
| Tinea | JP | 11 Apr 2005 | |
| Tinea Versicolor | JP | 11 Apr 2005 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Candidiasis, Chronic Mucocutaneous | Discovery | US | 11 Jan 2011 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 4 | 30 | (Tinea Pedis) | uyeqxhkair(lzbsioqaog) = vdukjcjfml dfqesggufe (xfdpamiqtp, vrmbnjjbog - prjzpqvdkn) View more | - | 27 Nov 2019 | ||
(Tinea Cruris) | kmrmeaerjv(pswflazmqe) = dnpdyrtqdy kmflolvunx (sfrssnfipu, tzdthuugas - gqfooakqki) View more | ||||||
Phase 4 | 75 | (Luliconazole Cream 1%) | stszlpwset(fmznvlsepi) = ejqjewetgg rjyfzrqpdm (gjpzfrzbvd, egygbdjhcg - ywmeidtkwg) View more | - | 27 Nov 2019 | ||
Vehicle Cream (Vehicle Cream) | stszlpwset(fmznvlsepi) = rglwetigdt rjyfzrqpdm (gjpzfrzbvd, rcpekyrbkq - jsusqrumvo) View more | ||||||
Phase 4 | 20 | shteokrqrg(lxrowuyeca) = kywyzuxedh csfksqxyhf (ohskhafdmz, freywtarcz - dgpjnxkuxf) View more | - | 27 Nov 2019 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free